Garda Capital Partners’s Blueprint Medicines BPMC Stock Holding History

Garda Capital Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,600	Closed	-$1.03M	–	559
2025 Q1	$1.03M	Buy	+11,600	New	+$1.13M	0.03%	441

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Garda Capital Partners's BPMC Position: Q2 2025 in Review

Garda Capital Partners sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 2,984 shares — an estimated $310K sold.

Garda Capital Partners first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $264K in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Garda Capital Partners reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Garda Capital Partners sold 2,984 Blueprint Medicines shares in Q2 2025, an estimated $310K.
Garda Capital Partners first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
Garda Capital Partners's Blueprint Medicines position peaked at $264K in Q1 2025.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Garda Capital Partners's 13F filing for Q2 2025, filed 7 Aug 2025.